Introduction
renal pelvis and infiltrating the graft, perirenal fat and connective tissue. The patient was reoperated in February 1997, but died in April 1997 from widespread Patients who undergo renal allotransplantation (RAT ) cancer of the abdomen. and subsequent immunosuppressive therapy are at During the initial 20 years the immunosuppressive increased risk of developing malignancies. We observed treatment consisted of prednisone and azathioprine, a case of widespread transitional-cell carcinoma, develand subsequently of prednisolone and cyclosporin. oping 25 years after transplantation in a renal allograft
The recipient was a smoker until 1994. The donor that had failed to function for 5 years. The case of the second graft was a middle-aged man (born illustrates the importance of careful monitoring or 1914) who had died from a subarachnoid haemorrhage. removal of a non-functioning graft.
Unfortunately the occupation of the donor and his smoking status are unknown. There was no evidence of malignant disease in this nor any of the other Case two donors. A man aged 22 with no previous history of renal disease presented in February 1971 with hypertension, oedema, and terminal renal insufficiency. Open renal Discussion biopsy showed changes consistent with an advanced chronic glomerulonephritis and severe hypertensive Recipients of renal transplants are at increased risk of vessel changes. Since his hypertension was uncontrol-developing malignancies. In a large Nordic study [1] lable by intensive oral and intravenous medication, a 2-5-fold increased risk for cancers of the colon, bilateral nephrectomy was performed in April 1971 larynx, lung, bladder, prostate, and testis was found, and the patient began haemodialysis (HD).
whereas there was a 10-30-fold increase of the risk of He had an unsuccessful RAT in June 1971 (the graft developing non-Hodgkin's lymphoma or cancer of the being removed shortly after), and a second RAT in lip, skin (non-melanoma), endocrine glands, kidneys, December 1971. This graft functioned for 20 years. and lower genital tract (women), as compared to the The non-functioning second graft was left in the left background population. Other studies [2, 3] confirm fossa iliaca, and he received a third RAT in June 1992. that the most frequent tumours seen after kidney This graft continued to function. transplantation are malignant lymphomas, cancers of Beginning in November 1996 the patient complained the skin (especially squamous-cell carcinoma) and of of increasing pain in the region of the second non-the urogenital system. functioning graft. Clinical examination revealed local Patients with analgesic nephropathy or acquired tenderness of the graft which felt firm and enlarged. cystic disease of their native kidneys have especially Blood tests showed moderately elevated serum high risks of developing carcinomas of the pelvis and C-reactive protein and alkaline phosphatase, and slight renal adenocarcinoma respectively. The cancer risk leukocytosis. Ultrasound examination of the graft seems to be independent of the number of performed revealed signs of calcification and a narrow low-transplantations [1, 2] . eccogenic edge at its lower part. The graft was surgicUrological malignancies are relatively common in renal-transplant patients. Most of the urological tumours are renal-cell carcinomas [5, 6 ] . In the Nordic Transitional-cell carcinoma in a 25-year-old renal allograft 3241 58 of the 471 cancers. The observed to expected ratios poorly studied subject. Graft failure occurring early after transplantation will nearly always lead to removal (SIR) for the urinary system cancers were highest in of the graft. When the graft failure occurs later, as the first years of follow up.
in our case, there is no general agreement whether Cancer in grafts is not a very common condition. It the graft should be removed or left in place. can either occur de novo, or be present at the time of Vanrenterghem and Khamis [9] recently reported that the transplantation [2] . In a study by Penn [7] comprissurgical removal of the graft was a safe procedure, ing 7596 kidney recipients with 8091 de novo tumours, recording no mortality in a group of 90 nephrectomized primary renal carcinomas accounted for 4.6% of patients, and severe complications occurring in less all cancers in renal-transplant patients when nonthan 10%. Although 25 (28%) of the patients had melanoma skin cancers and in situ cancers of the cervix carried their grafts for more than 6 months, the were excluded. The tumour involved the native kidney removal of very old grafts may carry a different in 222 of 256 patients and the allograft in 24 patients prognosis, since these patients may be older and the (in 10 cases the site was not stated ). Transitional-cell surgical procedure more complicated. carcinoma of the allograft was found in five of the 256
Our case illustrates the well-known need to bear de novo kidney tumours.
constantly in mind the increased cancer risk in Gaya et al. [3] found that the relative risk for nonimmunosuppressed renal transplant patients. In parskin cancers was not increased from 5 to 15 years postticular biologically old non-functioning grafts should transplantation. The cumulative risk of non-skin be carefully monitored, if not simply removed. cancer development, however, rose from 12.7% at 10 years to 31.9% after 20 years. In a single-centre retrospective cohort study [8] the long-term cumulative risk References of developing neoplasia after renal transplantation was 1995; 60: 183-189 general population was reported to be 6%). Nephrol Dial Transplant 1996; 11: 955-958 The management of the failed renal allograft is a
